About Cytoki

The Cytoki Story

Cytoki Pharma is a biotechnology company focused on serious diseases caused by epithelial injury with unmet medical need. The company was founded in 2019 after licensing of full pharma program from Novo Nordisk with seed financing from Lundbeckfonden Emerge, followed by a $45 M series A from a syndicate of strong international investors. Cytoki is run by a team of experienced pharma executives with deep expertise in IL-22 biology, lipidation technology and drug development. Our long-acting lipidated IL-22 analogue program with promise as treatment for diseases involving epithelial injury - particularly IBD - is on track for Phase 1 start in late 2022.

Our team

Rasmus Jorgensen, PhD


Anne Louise Kjølbye, PhD, MBA

Chief Development Officer

Martijn van de Bunt, MD, DPhil

Vice President of Research

Jens Chr. Norrild, PhD

Vice President of CMC

Karsten Skydsgaard, DVM, E*MBA

Head of Non-Clinical Development

Our board

Christian Elling

Chairperson and Managing Partner, Lundbeckfonden BioCapital

Karen Wagner

Managing Partner, Ysios Capital

Dani Bach

Partner, +ND Capital

Amanda Chaperot

Partner, Seventure Partners

Our investors